关注
Marcus Thuresson
Marcus Thuresson
Statisticon AB
在 statisticon.se 的电子邮件经过验证
标题
引用次数
引用次数
年份
Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective
T Jernberg, P Hasvold, M Henriksson, H Hjelm, M Thuresson, M Janzon
European heart journal 36 (19), 1163-1170, 2015
9212015
Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative …
M Kosiborod, MA Cavender, AZ Fu, JP Wilding, K Khunti, RW Holl, ...
Circulation 136 (3), 249-259, 2017
7422017
Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study
M Kosiborod, CSP Lam, S Kohsaka, DJ Kim, A Karasik, J Shaw, N Tangri, ...
Journal of the American College of Cardiology 71 (23), 2628-2639, 2018
4692018
Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs …
KI Birkeland, ME Jørgensen, B Carstensen, F Persson, HL Gulseth, ...
The lancet Diabetes & endocrinology 5 (9), 709-717, 2017
3782017
Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study
HJL Heerspink, A Karasik, M Thuresson, C Melzer-Cohen, G Chodick, ...
The lancet Diabetes & endocrinology 8 (1), 27-35, 2020
2982020
Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes (CVD‐REAL Nordic) when compared with dipeptidyl …
F Persson, T Nyström, ME Jørgensen, B Carstensen, HL Gulseth, ...
Diabetes, Obesity and Metabolism 20 (2), 344-351, 2018
2212018
CVD-REAL Investigators and Study Group. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering …
M Kosiborod, MA Cavender, AZ Fu, JP Wilding, K Khunti, RW Holl, ...
Circulation 136 (3), 249-59, 2017
1882017
Amputation rates, mortality, and pre-operative comorbidities in patients revascularised for intermittent claudication or critical limb ischaemia: a population based study
EB Fridh, M Andersson, M Thuresson, B Sigvant, B Kragsterman, ...
European Journal of Vascular and Endovascular Surgery 54 (4), 480-486, 2017
1772017
Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: a large multinational cohort study
KI Birkeland, J Bodegard, JW Eriksson, A Norhammar, H Haller, ...
Diabetes, obesity and metabolism 22 (9), 1607-1618, 2020
1722020
Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2· 4 million patients from 11 countries: The CaReMe CKD study
J Sundström, J Bodegard, A Bollmann, MG Vervloet, PB Mark, A Karasik, ...
The Lancet Regional Health–Europe 20, 2022
1672022
Intrahepatic cholestasis of pregnancy and cancer, immune-mediated and cardiovascular diseases: A population-based cohort study
EAW Shemer, O Stephansson, M Thuresson, M Thorsell, JF Ludvigsson, ...
Journal of hepatology 63 (2), 456-461, 2015
1642015
Low-dose aspirin discontinuation and risk of cardiovascular events: a Swedish nationwide, population-based cohort study
J Sundström, J Hedberg, M Thuresson, P Aarskog, KM Johannesen, ...
Circulation 136 (13), 1183-1192, 2017
1502017
Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden …
A Norhammar, J Bodegård, T Nyström, M Thuresson, JW Eriksson, ...
Diabetologia 59, 1692-1701, 2016
1422016
Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and …
S Nilsson, L Franzén, C Parker, C Tyrrell, R Blom, J Tennvall, ...
Clinical genitourinary cancer 11 (1), 20-26, 2013
1422013
Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma
PG Richardson, A Oriol, A Larocca, J Bladé, M Cavo, P Rodriguez-Otero, ...
Journal of Clinical Oncology 39 (7), 757-767, 2021
1302021
Using big data from health records from four countries to evaluate chronic disease outcomes: a study in 114 364 survivors of myocardial infarction
E Rapsomaniki, M Thuresson, E Yang, P Blin, P Hunt, SC Chung, ...
European Heart Journal–Quality of Care and Clinical Outcomes 2 (3), 172-183, 2016
1302016
Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality
JW Eriksson, J Bodegard, D Nathanson, M Thuresson, T Nyström, ...
Diabetes research and clinical practice 117, 39-47, 2016
1292016
SGLT-2 inhibitors and cardiovascular risk: an analysis of CVD-REAL
MA Cavender, A Norhammar, KI Birkeland, ME Jørgensen, JP Wilding, ...
Journal of the American College of Cardiology 71 (22), 2497-2506, 2018
1222018
Lower risk of heart failure and death in patients initiated on SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study
M Kosiborod, MA Cavender, AZ Fu, JP Wilding, K Khunti, RW Holl, ...
Circulation 136 (3), 249-259, 2017
1222017
Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden)
G Savarese, J Bodegard, A Norhammar, P Sartipy, M Thuresson, ...
European journal of heart failure 23 (9), 1499-1511, 2021
1212021
系统目前无法执行此操作,请稍后再试。
文章 1–20